Is oxaliplatin the optimal platinum agent in gastric cancer?

European Journal of Cancer, Supplement

Volumn 4, Issue 10, 2006, Pages 10-13

  Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Gastric cancer; Oxaliplatin; Platinum

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL TRIAL; CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; ESOPHAGUS CANCER; HUMAN; LOWER ESOPHAGUS SPHINCTER; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER;

EID: 33845380264     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)70003-9     Document Type: Article

References (28)

1. Webb A., Cunningham D., Scarffe J., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
2. Waters J., Norman A., Cunningham D., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. Br J Cancer 80 (1999) 269-272
3. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1996-2004
4. Wagner A., Grothe W., Behl S., et al. Chemotherapy for advanced gastric cancer. Coch Database Sys Rev 18 (2005) CD004064
5. Raymond E., Faivre S., Woynarowski J., and Chaney S. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 2 Suppl 5 (1998) 4-12
6. Mathe G., Kidani Y., Segiguchi M., et al. Oxalato-platinum or I-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43 (1989) 237-250
7. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1 (2002) 227-235
8. Grothey A., and Goldberg R. A review of oxaliplatin and its clinical use in colorectal cancer. Exp Opin Pharmacother 5 (2004) 2159-2170
9. Rothenberg M., Oza A., Bigelow R., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
10. Hartmann J., and Lipp H. Toxicity of platinum compounds. Exp Opin Pharmacother 4 (2003) 889-901
11. Eriguchi M., Nonaka Y., Yanagie H., Yoshizaki I., Takeda Y., and Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anticancer agent oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 57 (2003) 412-415
12. Cunningham D., Rao S., Starling N., et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 24 Suppl 18 (2006) 182s (Abstract LBA4017)
13. Louvet C., Andre T., Tigaud J., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20 (2002) 4543-4548
14. Bang Y., Kang Y., Kang W., et al. Phase II study of oxaliplatin, 5-fluorouracil and folinic acid in recurrent or-metastatic gastric cancer. Proc Am Soc Clin Oncol 21 (2002) (Abstract 2249)
15. Al-Batran S., Atmaca A., Hegewisch-Becker S., et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22 (2004) 658-663
16. Chao Y., Yeh K., Chang C., et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91 (2004) 453-458
17. Jin M., Chen Q., Cheng F., et al. Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 21 (2002) (Abstract 558)
18. Mauer A., Kraut E., Rudin C., et al. Phase II study of oxaliplatin (OX), fluorouracil (FU) and leucovorin (LV) in metastatic carcinoma of the esophagus/gastric carda. Proc Am Soc Clin Oncol 21 (2002) (Abstract 554)
19. De Vita F., Orditura M., Matano E., et al. A phase II study of biweekly oxaliplatin plus inftusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92 (2005) 1644-1649
20. Iop A., Bonura S., Manfredi A., and Artioli F. Combination of oxaliplatin, 5-fluorouracil and folinic acid in advanced metastatic gastric carcinoma. Proc Am Soc Clin Oncol 23 (2004) (Abstract 60)
21. Duyster J., Lorenzen S., Kullmann F., et al. Oxaliplatin plus 5-FU/folinic acid (FUFOX regimen) in first-line metastatic gastric cancer (MGC). Results of the multicenter phase II STOMOX. J Clin Oncol 23 Suppl 16 (2005) 311s (Abstract 4016)
22. Kim H., Kwon H., Oh S., et al. A phase II study of oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced or metastatic gastric cancer. J Clin Oncol 24 Suppl 18 (2006) 628s (Abstract 14052)
23. Lordick F., Lorenzen S., Stollfuss J., et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93 (2005) 190-194
24. Moiseyenko V., Ajani J., Tjulandin S., et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) in patients (pts) with metastatic gastric adenocarcinoma. J Clin Oncol 23 Suppl 16 (2005) 308s (Abstract 4002)
25. Moiseyenko V, Van Cutsem E, Tjulandin S, et al. Adding docetaxel to cisplatin-5-fluorouracil improves quality of life in advanced gastric cancer: a phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15-18 June 2005 (Abstract O-013).
26. Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Docetaxel when added to cisplatin-5-fluorouracil improves survival in advanced gastric cancer: a phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15-18 June 2005 (Abstract O-012).
27. Richards D., Wilfong L., Reznick D., et al. Phase II multicenter trial of docetaxel + oxaliplatin in stage IV gastroesophageal and/or stomach cancer. J Clin Oncol 24 Suppl 18 (2006) 195s (Abstract 4071)
28. Barone C., Basso M., Quirino M., et al. Docetaxel and oxaliplatin combination as second line treatment in patients with advanced gastric cancer. ASCO Gastro-intestinal Cancers Symposium, Hollywood, Florida (27-29 January 2005) (Abstract 27)